Obesity rate in the US: 40% Obesity rate in Japan: 3% Insane how big of a difference this is in two industrialized nations. Theyre not doing keto, cold plunges or even blocking blue light at night... Everyone basically eats rice, noodles, fish & meat with very moderate portion sizes. Real food, made with traditional recipes. This is the way

Obesity raises the risk of type 2 diabetes and cardiovascular disease. A post-hoc analysis showed our oral obesity medicine was associated with reductions in the predicted risk of both conditions, with reductions seen across all doses. Read more:

Obesity and type 2 diabetes rarely occur alone. That's why it's important to have treatment options that address different patient's needs. This is the thinking behind our work at the upcoming #EASD2026# conference in Milan, Italy. Read more about our approach:

Treating obesity & type 2 diabetes together can be challenging, but new research presented at #EASD2026# showed our investigational treatment, when taken at the highest dose, helped more than half of participants no longer have obesity, and nearly 40% reach a normal A1C.

$VKTX OBESITY DRUG MAINTAINS MOST WEIGHT LOSS WITH LESS-FREQUENT DOSING Viking Therapeutics says VK2735 maintained up to 97% of prior weight loss when patients moved from weekly injections to every-other-week dosing, and up to 90% with monthly dosing over 12 weeks. Before the maintenance phase, patients had lost roughly 16%-19% of body weight over 21 weeks. An exploratory group that stayed on weekly 17.5 mg dosing reached about 22% weight loss by week 33, with no plateau observed. GI side effects during maintenance were similar to placebo, and discontinuations remained low. Viking plans to test oral maintenance dosing next. VK2735 is already in Phase 3 development for obesity.